JPH0415764B2 - - Google Patents

Info

Publication number
JPH0415764B2
JPH0415764B2 JP60049664A JP4966485A JPH0415764B2 JP H0415764 B2 JPH0415764 B2 JP H0415764B2 JP 60049664 A JP60049664 A JP 60049664A JP 4966485 A JP4966485 A JP 4966485A JP H0415764 B2 JPH0415764 B2 JP H0415764B2
Authority
JP
Japan
Prior art keywords
skin
weight
present
arbutin
effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60049664A
Other languages
Japanese (ja)
Other versions
JPS61207317A (en
Inventor
Yoshimori Fujinuma
Hidekazu Toyoda
Shuya Tamaoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP4966485A priority Critical patent/JPS61207317A/en
Publication of JPS61207317A publication Critical patent/JPS61207317A/en
Publication of JPH0415764B2 publication Critical patent/JPH0415764B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

[産業上の利用分野] 本発明は皮膚美白効果、色素沈着症治療効果が
著しく改良された安全性の高い皮膚外用剤に関す
る。 [従来の技術] 皮膚のしみなどの発生機序については不明な点
もあるが、一般には、ホルモンの異常や日光から
の紫外線の刺激が原因となつてメラニン色素が形
成され、これが皮膚内に異常沈着するものと考え
られている。このようなしみやあざの治療法には
メラニンの生成を抑制する物質、例えばビタミン
Cを大量に投与する方法、グルタチオン等を注射
する方法あるいはL−アスコルビン酸、システイ
ンなどを軟膏、クリーム、ローシヨンなどの形態
にして、局所に塗布するなどの方法がとられてい
る。また欧米ではハイドロキノン製剤が医薬品と
して用いられている。 [発明が解決しようとする問題点] しかしながらL−アスコルビン酸類は安定性の
面で問題があり、水分を含む系では不安定で変
色、変臭の原因となり、グルタチオン、システイ
ンなどのチオール系化合物は異臭が強い上、酸化
されやすく化粧料等への配合は避けられている。
さらにこれらの化合物はハイドロキノンを除いて
はその効果の発現がきわめて緩慢であるため、美
白効果が十分でない。一方、ハイドロキノンは効
果は一応認められているが、極めて不安定な物質
で外用剤基剤に配合すると経時で分解、重合、着
色等変質し易く、また感作性等の安全性の点で好
ましくない為、一般には使用が制限されている。 このような事情に鑑み、本発明者等は色素沈着
症治療効果、皮膚の美白効果に優れ、かつ安全
性、安定性にも優れた皮膚外用剤を得るべく鋭意
研究を重ねた結果、特定のハイドロキノン配糖体
が上記目的に合致することを見出し、この知見を
基にさらに研究を重ねた結果、特定の製剤処方を
取ることによりハイドロキノン配糖体の色素沈着
症治療効果、皮膚の美白効果が最大限に発揮され
ることを見出した。 本発明はこれらの知見にもとずいて完成させた
ものである。 [問題点を解決するための手段] すなわち本発明はアルブチン(ハイドロキノン
−β−D−グルコース)0.1〜30重量%、水溶性
増粘剤0.01〜5重量%および低級アルコール0.3
〜35重量%を必須成分として含有し、アルブチン
と低級アルコールの比が3:1〜1:3であるこ
とを特徴とする皮膚外用剤 を提供するものである。 以下、本発明の構成について詳述する。 アルブチンの配合量は皮膚外用全量中の0.1〜
30重量%であり、好ましくは6〜20重量%であ
る。 0.1重量%未満では、色素沈着症治療効果の面
で弱く、30重量%を超えて配合しても効果の大幅
な増大は望めず、かえつて皮膚外用剤としての安
定性を悪くする場合も生じるので好ましくない。 本発明に用いる水溶性増粘剤としては例えばア
ラビアガム、トラガガントガム、ガラクタン、グ
アガム、カラギーナン、ペクチン、クインスシー
ド(マルメロ)抽出物、褐藻粉末等の植物系高分
子、キサンタンガム、デキストラン、プルラン等
の微生物系高分子、コラーゲン、カゼイン、アル
ブミン、ゼラチン等の動物系高分子、カルボキシ
メチルデンプン、メチルヒドロキシデンプン等の
デンプン類、メチルセルロース、ニトロセルロー
ス、エチルセルロース、メチルヒドロキシプロピ
ルセルロース、ヒドロキシエチルセルロース、セ
ルロース硫酸塩、ヒドロキシプロピルセルロー
ス、カルボキシメチルセルロース、結晶セルロー
ス、セルロース末等のセルロース類、ポリビニル
アルコール、ポリビニルメチルエーテル、ポリビ
ニルピロリドン、カルボキシビニルポリマー等の
ビニル系高分子、ポリアクリル酸およびその塩、
ポリアクリルイミド等のアクリル系高分子、その
他グリチルリチン酸やアルギン酸およびその塩等
があげられる。 またベントナイト、ラポナイト、ヘクトライ
ト、ケイ酸アルミニウムマグネシウム、無水ケイ
酸などの無機系増粘剤も用いることができる。 これらの中でポリアクリル酸およびその塩が特
に好適に用いられる。配合量は皮膚外用剤全量中
の0.01〜5重量%であり、好ましくは0.1〜3重
量%である。 本発明に用いる低級アルコールとしては、エタ
ノール、イソプロパノールがあげられる。配合量
は皮膚外用剤全量中0.3〜35重量%である。 本発明の皮膚外用剤において、ハイドロキノン
の配糖体と低級アルコールとの配合比は、効果発
現性、安定性の面から3:1〜1:3であること
が好ましい。 本発明の皮膚外用剤には上記した必須構成成分
の他に、化粧料、医薬品等に一般に用いられる各
種成分、すなわち界面活性剤、油分、紫外線吸収
剤、酸化防止剤、防腐剤、保湿剤、香料、水、ア
ルコール、PH調整剤等を必要に応じて適宜配合す
ることができる。特に紫外線吸収剤を併用するこ
とは、効果を増大させる点で好ましい。 本発明の皮膚外用剤は水性のローシヨン、乳
液、および増粘ゲル系を呈する。 [発明の効果] 本発明の皮膚外用剤は色素沈着症治療効果、皮
膚の美白効果に優れ、かつ安全性、安定性にも優
れたものである。 [実施例] 以下、実施例をあげて本発明をさらに詳細に説
明するが本発明はこれらの実施例に限定されるも
のではない。 配合量は重量%である。 実施例1〜4、比較例1および2
[Industrial Application Field] The present invention relates to a highly safe external skin preparation that has significantly improved skin whitening effects and pigmentation treatment effects. [Conventional technology] Although there are some points that are unclear about the mechanism by which skin spots occur, in general, melanin pigments are formed due to hormonal abnormalities or stimulation of ultraviolet rays from sunlight, and this is caused by the formation of melanin within the skin. It is thought that it is abnormally deposited. Treatments for these spots and bruises include administering large amounts of substances that suppress melanin production, such as large doses of vitamin C, injections of glutathione, or the use of ointments, creams, and lotions containing L-ascorbic acid, cysteine, etc. Methods such as making it into a form and applying it locally are used. Additionally, hydroquinone preparations are used as pharmaceuticals in Europe and America. [Problems to be Solved by the Invention] However, L-ascorbic acids have problems in terms of stability, and are unstable in systems containing water, causing discoloration and odor, and thiol compounds such as glutathione and cysteine It has a strong odor and is easily oxidized, so its inclusion in cosmetics is avoided.
Furthermore, these compounds, with the exception of hydroquinone, exhibit very slow effects and therefore do not have sufficient whitening effects. On the other hand, although hydroquinone has been recognized to be effective, it is an extremely unstable substance that tends to deteriorate over time, such as decomposition, polymerization, and discoloration when added to the base of external preparations, and is not preferred in terms of safety such as sensitization. Because of this, its use is generally restricted. In view of these circumstances, the present inventors have conducted extensive research to obtain a topical skin preparation that has excellent pigmentation treatment effects and skin whitening effects, as well as excellent safety and stability. We found that hydroquinone glycosides met the above objectives, and based on this knowledge, we conducted further research and found that by taking a specific formulation, hydroquinone glycosides can be effective in treating pigmentation and skin whitening. I have found that it works to its full potential. The present invention was completed based on these findings. [Means for Solving the Problems] That is, the present invention uses 0.1 to 30% by weight of arbutin (hydroquinone-β-D-glucose), 0.01 to 5% by weight of a water-soluble thickener, and 0.3% of a lower alcohol.
The object of the present invention is to provide a skin preparation for external use, which contains arbutin in an amount of 35% by weight as an essential component, and is characterized in that the ratio of arbutin to lower alcohol is 3:1 to 1:3. Hereinafter, the configuration of the present invention will be explained in detail. The amount of arbutin included is 0.1 to 0.1 of the total amount for external skin use.
30% by weight, preferably 6-20% by weight. If the amount is less than 0.1% by weight, the therapeutic effect for pigmentation is weak, and if it is added in excess of 30% by weight, the effect cannot be expected to increase significantly, and the stability as an external skin preparation may be worsened. So I don't like it. Water-soluble thickeners used in the present invention include, for example, gum arabic, gum tragaganth, galactan, guar gum, carrageenan, pectin, quince seed (quince) extract, vegetable polymers such as brown algae powder, microorganisms such as xanthan gum, dextran, pullulan, etc. animal-based polymers such as collagen, casein, albumin, gelatin, starches such as carboxymethyl starch and methyl hydroxy starch, methyl cellulose, nitrocellulose, ethyl cellulose, methyl hydroxypropyl cellulose, hydroxyethyl cellulose, cellulose sulfate, hydroxy Celluloses such as propyl cellulose, carboxymethyl cellulose, crystalline cellulose, cellulose powder, vinyl polymers such as polyvinyl alcohol, polyvinyl methyl ether, polyvinyl pyrrolidone, carboxy vinyl polymer, polyacrylic acid and its salts,
Examples include acrylic polymers such as polyacrylimide, glycyrrhizinic acid, alginic acid, and salts thereof. Inorganic thickeners such as bentonite, laponite, hectorite, magnesium aluminum silicate, and silicic anhydride can also be used. Among these, polyacrylic acid and its salts are particularly preferably used. The blending amount is 0.01 to 5% by weight, preferably 0.1 to 3% by weight, based on the total amount of the skin external preparation. Examples of lower alcohols used in the present invention include ethanol and isopropanol. The blending amount is 0.3 to 35% by weight based on the total amount of the skin external preparation. In the skin external preparation of the present invention, the blending ratio of hydroquinone glycoside and lower alcohol is preferably 3:1 to 1:3 in terms of effectiveness and stability. In addition to the above-mentioned essential components, the external skin preparation of the present invention includes various components commonly used in cosmetics, pharmaceuticals, etc., such as surfactants, oils, ultraviolet absorbers, antioxidants, preservatives, humectants, Flavors, water, alcohol, PH adjusters, etc. can be added as appropriate. In particular, it is preferable to use an ultraviolet absorber in combination in order to increase the effect. The skin external preparation of the present invention is an aqueous lotion, milky lotion, or thickened gel system. [Effects of the Invention] The skin external preparation of the present invention has an excellent effect on treating pigmentation disorders and a skin whitening effect, and is also excellent in safety and stability. [Examples] Hereinafter, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to these Examples. The blending amount is in weight%. Examples 1 to 4, Comparative Examples 1 and 2

【表】 上表の配合組成よりなるゲルを常法により調整
し、その累積塗布による美白効果について調べ
た。美白効果は、累積塗布による皮膚に対する色
白効果、シミ、ソバカスの解消などの使用テスト
から判定した。 累積塗布による美白効果試験 (試験方法) 色黒、しみ、そばかす等に悩む、被試験者、1
群20名として、1つの試料ゲルを朝夕、3ケ月
間、毎日顔面に塗布し、3ケ月目にその美白効果
を調べた。 (判定基準) 著 効:色素沈着がほとんど目立たなくなつ
た。 有 効:非常にうすくなつた。 やや有効:ややうすくなつた。 無 効:変化無し (判定) ◎:被試験者のうち著効、有効の示す割合(有効
率)が80%以上の場合 〇:被試験者のうち著効、有効の示す割合(有効
率)が60%以上80%未満の場合 △:被試験者のうち著効、有効の示す割合(有効
率)が40%以上60未満の場合 ×:被試験者のうち著効、有効の示す割合(有効
率)が40%未満の場合 結果を下表に示す。
[Table] A gel having the composition shown in the table above was prepared by a conventional method, and the whitening effect of cumulative application was investigated. The whitening effect was determined from use tests such as skin whitening effect upon cumulative application, and elimination of age spots and freckles. Whitening effect test by cumulative application (test method) Test subject suffering from dark skin, age spots, freckles, etc., 1
A group of 20 people applied one sample gel to their faces in the morning and evening every day for three months, and the whitening effect was examined after the third month. (Judgment criteria) Results: Pigmentation became almost invisible. Effective: Very pale. Slightly effective: Slightly less effective. Ineffective: No change (judgment) ◎: If the percentage of test subjects who show an excellent response or efficacy (effective rate) is 80% or more 〇: The percentage of test subjects who show an excellent response or effective response (effective rate) is 60% or more and less than 80% △: If the percentage of test subjects who show an excellent response or effective response (effective rate) is 40% or more and less than 60 ×: The percentage of test subjects who show an excellent response or effective response ( If the effectiveness rate) is less than 40%, the results are shown in the table below.

【表】 上表から明らかなように、本発明の皮膚外用剤
は美白効果に優れる新規な皮膚外用剤である。 実施例5 水性ローシヨン 常法により下記処方の水性ローシヨンを得た。 アルブチン 15.0 クインスシード抽出物 0.2 エタノール 25.0 グリセリン 1.5 プロピレングリコール 1.0 POE(20)オレイルアルコールエーテル 1.5 トコフエリルアセテート 0.03 香 料 適量 防腐剤 適量 イオン交換水 残余 実施例6 乳液 常法により下記処方の乳液を得た。 アルブチン 10.0 エタノール 10.0 カルボキシビニルポリマー 0.3 ペンタエリスリトールテトラオクチルエステル
3.0 オクチルジメチルパラアミノ安息香酸エステル
2.0 シリコンKF96A6(信越化学社製) 2.0 POE(15)ジヒドロコレステロールエーテル 1.0 1,3−ブチレングリコール 5.0 グリセリン 3.0 香料 適量 防腐剤 適量 カセイソーダ 0.1 イオン交換水 残余 実施例5および実施例6は実施例1〜4同様皮
膚美白効果に優れた安全性良好な皮膚外用剤であ
つた。
[Table] As is clear from the above table, the skin external preparation of the present invention is a novel skin external preparation with excellent whitening effects. Example 5 Aqueous lotion An aqueous lotion having the following formulation was obtained by a conventional method. Arbutin 15.0 Quince seed extract 0.2 Ethanol 25.0 Glycerin 1.5 Propylene glycol 1.0 POE (20) oleyl alcohol ether 1.5 Tocopheryl acetate 0.03 Flavor Appropriate amount Preservative Appropriate amount Ion-exchanged water Remaining Example 6 Emulsion Emulsion with the following formulation was obtained by a conventional method . Arbutin 10.0 Ethanol 10.0 Carboxyvinyl Polymer 0.3 Pentaerythritol Tetraoctyl Ester
3.0 Octyldimethyl para-aminobenzoic acid ester
2.0 Silicone KF96A6 (manufactured by Shin-Etsu Chemical Co., Ltd.) 2.0 POE (15) dihydrocholesterol ether 1.0 1,3-butylene glycol 5.0 Glycerin 3.0 Flavor Appropriate amount Preservative Appropriate amount Caustic soda 0.1 Ion exchange water Residual Example 5 and Example 6 are based on Examples 1 to 6. Similar to No. 4, it was a skin external preparation with excellent skin whitening effects and good safety.

Claims (1)

【特許請求の範囲】[Claims] 1 アルブチン0.1〜30重量%、水溶性増粘剤
0.01〜5重量%および低級アルコール0.3〜35重
量%を必須成分として含有し、アルブチンと低級
アルコールの比が3:1〜1:3であることを特
徴とする皮膚外用剤。
1 Arbutin 0.1-30% by weight, water-soluble thickener
1. A skin preparation for external use, which contains 0.01 to 5% by weight and 0.3 to 35% by weight of lower alcohol as essential components, and is characterized in that the ratio of arbutin to lower alcohol is 3:1 to 1:3.
JP4966485A 1985-03-13 1985-03-13 External agent for skin Granted JPS61207317A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4966485A JPS61207317A (en) 1985-03-13 1985-03-13 External agent for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4966485A JPS61207317A (en) 1985-03-13 1985-03-13 External agent for skin

Publications (2)

Publication Number Publication Date
JPS61207317A JPS61207317A (en) 1986-09-13
JPH0415764B2 true JPH0415764B2 (en) 1992-03-19

Family

ID=12837442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4966485A Granted JPS61207317A (en) 1985-03-13 1985-03-13 External agent for skin

Country Status (1)

Country Link
JP (1) JPS61207317A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673536A1 (en) * 1991-03-08 1992-09-11 Beretz Pharmacie Labo Homme Fe Depigmenting preparation
JPH06256137A (en) * 1993-03-01 1994-09-13 Chugai Pharmaceut Co Ltd Beautifying dermatic external preparation
JP3544223B2 (en) * 1994-03-15 2004-07-21 三和生薬株式会社 New hair growth and hair growth promoter
CN111358745B (en) * 2020-04-14 2021-11-23 百肽德医药生物科技(广东)有限公司 Whitening, firming and moisturizing cream and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5781410A (en) * 1980-11-11 1982-05-21 Tokitaka Mori Remedy for skin pigmentation
JPS57145803A (en) * 1981-03-05 1982-09-09 Sunstar Inc External decoloring agent for skin
JPS6016906A (en) * 1983-07-07 1985-01-28 Pola Chem Ind Inc External drug for skin

Also Published As

Publication number Publication date
JPS61207317A (en) 1986-09-13

Similar Documents

Publication Publication Date Title
US5756107A (en) Formulations and methods for reducing skin irritation
US6455076B1 (en) Formulations and methods for reducing skin irritation
US5958436A (en) Formulations and methods for reducing skin irritation
US5716625A (en) Formulations and methods for reducing skin irritation
JP2502318B2 (en) Whitening cosmetics
US20030124202A1 (en) Formulations and methods for reducing skin irritation
WO1996019183A9 (en) Formulations and methods for reducing skin irritation
EP0954274A1 (en) Topical product formulations containing strontium for reducing skin irritation
CA2208268A1 (en) Formulations and methods for reducing skin irritation
WO1996019228A9 (en) Formulations and methods for reducing skin irritation
CN111936130B (en) Topical preparations and treatments containing strontium and methylsulfonylmethane (MSM)
JPH0533683B2 (en)
JPH0415764B2 (en)
JPS625909A (en) Preventing agent for skin elastosis
JPH01249714A (en) Skin cosmetic
JP2000290177A (en) Nitrogen monoxide scavenger and aging-protecting cosmetic material
JP3004707B2 (en) External preparation for skin
JP2002234828A (en) Skin whitening cosmetic preparation
JP2006022090A (en) Inflammation inhibitor comprising pyrrolidone carboxylic acid zinc salt
JP3026616B2 (en) Whitening cosmetics
JPH09132527A (en) Suppressant for melanogenesis and dermal preparation for external use
JPH0692833A (en) Skin external agent
JP4524221B2 (en) Topical skin preparation
JP4761852B2 (en) Topical skin preparation
JP2005089309A (en) Cosmetic for treating roughening of lip

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term